Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 12/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 12/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | MLYCD | O95822 | 1/20 | 0.40 |
| ▸ | SLC26A6 | Q9BXS9 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7661360 | 0.87 | GABRA2 (0.45) | GABRA2GABRB2MAPK9MLYCDSLC26A6 | |
| SCHEMBL7566543 | 0.84 | GABRA2 (0.48) | GABRA2GABRB2MAPK9MLYCDSYK | |
| SCHEMBL7665192 | 0.81 | MAPK14 (0.51) | GABRA2GABRB2MAPK9 | |
| SCHEMBL7665202 | 0.81 | MAPK14 (0.51) | GABRA2GABRB2MAPK9 | |
| SCHEMBL7664658 | 0.80 | MAPK9 (0.61) | GABRA2GABRB2MAPK9MLYCDSYK | |
| SCHEMBL7665355 | 0.78 | GABRA2 (0.48) | GABRA2GABRB2MAPK9MLYCDSYK | |
| SCHEMBL7534386 | 0.78 | GABRA2 (0.48) | GABRA2GABRB2MAPK9MLYCDSYK | |
| SCHEMBL7590696 | 0.71 | MAPK14 (0.52) | MAPK9FLT1FLT4KDR | |
| SCHEMBL7590690 | 0.71 | MAPK14 (0.52) | MAPK9FLT1FLT4KDR | |
| SCHEMBL31141725 | 0.68 | HDAC3 (0.67) | SLC26A6MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6492516-B1 | PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF WHICH EXHIBIT UTILITY FOR THE TREATMENT OF CYTOKINE MEDIATED DISEASES SUCH AS ARTHRITIS. | MERCK & CO., INC. | 2002-12-10 | — | — | US | disclosed |